Clinical Trial Update: Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on the combination of GT90001 with nivolumab in metastatic hepatocellular carcinoma (Phase 1/Phase 2) completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• GT90001
• nivolumab (nivolumab)

Snippet

Sponsor: Suzhou Kintor Pharmaceutical Inc, | Conditions: Metastatic Hepatocellular Carcinoma, HCC | Phase 1, Phase 2 | Status: COMPLETED